Washington Post
Darryl Fears
In a government lab where scientists slice open dead animals to study the exotic diseases that killed them, Carol Meteyer peered through a microscope at hundreds of little bats and started to notice something very weird.
The bats had managed to survive the white-nose fungus that had killed millions of other bats hibernating in caves, mostly in the Northeast. But they had succumbed to something else that had left their tiny corpses in tatters, their wings scorched and pocked with holes.
Meteyer, a scientist for the U.S. Geological Survey, had stumbled upon a phenomenon never before seen in mammals in the wild. A similar finding had been observed only once before — in people with AIDS.
Now scientists hope studying the immunology of bats might help in the development of treatments for AIDS.
The devastating immune-system attack, called IRIS for immune reconstitution inflammatory syndrome, plays out differently in humans and bats, according to an article by Meteyer and two colleagues that recently appeared in the journal Virulence.
When bats hibernate in winter, their heart rates slow and their immune systems all but shut down, making them vulnerable to the cave-dwelling fungus Geomyces destructansthat causes white-nose and eats away skin, connective tissue and muscle.
When bats wake up in late March, their immune systems react like startled homeowners who realize prowlers are inside the house. They launch a wild search-and-destroy mission that annihilates the disease, but also healthy cells and tissue.
“It’s not natural. It’s cellular suicide. It comes out in a huge wave, going out to those areas of infection and kills everything,” said Meteyer, who was a veterinary pathologist for the USGS in Madison, Wis., at the time of her discovery but now is the deputy coordinator for contaminant biology for the agency in Reston.
For AIDS patients, the immune-system syndrome plays out differently. After antiretroviral treatment improves patients’ health, their restored immune systems can launch an exaggerated attack against any previously acquired opportunistic infection the treatment didn’t catch, causing extensive damage.
Scientists now hope to study the immunology of bats to try to uncover findings that can assist the development of treatments for AIDS.
Meteyer said she envisions a day when “we can look closely at the mechanism driving this intense response in bats and potentially get insight into this phenomenon in humans.”
Her co-author, Judith Mandl, a research fellow for the National Institutes of Health involved in AIDS research, was also intrigued by the similarities between bat and human reactions. “When you release immune suppression, you get a response that’s a lot more damaging than helpful,” she said. The third co-author is Daniel Barber, who also works at NIH.
Eleftherios Mylonakis, Virulence’s editor-in-chief, said he included the research in the Nov. 15 edition because it represents the “out of the box” thinking the journal seeks to capture. “We want to support scientists thinking in novel ways,” he said. “Very often what we see in our patients is already seen in some form or another in nature and we want to understand these connections in order to facilitate new discoveries.”
